

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK – 18 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Anouska Penny-Gibson, a person closely associated (PCA) to Steve Gibson, a PDMR of Novacyt, acquired 697 ordinary shares of €1/15 each in the Company at an average price of £8.59 per share. The resultant beneficial shareholding of Mr. Gibson is 9,116 ordinary shares representing 0.01% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated									
a)	Name	Anouska Penny-Gibson								
2.	Reason for the Notification									
a)	Position/status	PCA to Steve Gibson (PDMR)								
b)	Initial notification/ Amendment	Initial Notification								
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor									
a)	Name	Novacyt S.A.								
b)	LEI	213800BWAC2BF295EG28								
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted									
a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each								
	Identification code	FR0010397232								
b)	Nature of the transaction	Acquisition of Ordinary Shares								
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£8.88</td> <td>111</td> </tr> <tr> <td>£8.57</td> <td>231</td> </tr> <tr> <td>£8.41</td> <td>355</td> </tr> </tbody> </table>	Price	Volume	£8.88	111	£8.57	231	£8.41	355
Price	Volume									
£8.88	111									
£8.57	231									
£8.41	355									
d)	Aggregated information: · Aggregated volume · Price	<table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£8.59</td> <td>697</td> </tr> </tbody> </table>	Price	Volume	£8.59	697				
Price	Volume									
£8.59	697									

e)	Date of the transaction	12 November 2020
f)	Place of the transaction	London Stock Exchange, AIM

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com